Search
Clene Inc.
CLNNAdd to Watchlist
6.100USD
-0.030-0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
77.95MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Clene Inc. is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 48.00 and a low of 23.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
32.200
Target Price
+408.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Clene Inc.
CLNN
5
Beigene Ltd
ONC
27
Ionis Pharmaceuticals Inc
IONS
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Clene Inc.'s expected revenue for the next quarter?
Clene Inc.'s expected revenue is 73.50K.
What is Clene Inc.'s price target?
Analysts forecast that Clene Inc.'s price target is USD 30.00, with the highest forecast at USD 48.00 and the lowest forecast at USD 23.00.
How have Clene Inc.CLNN's recent earnings per share performed?
The market expectation was USD -0.69, while Clene Inc.CLNN's earnings per share (EPS) for the previous quarter was USD -0.86. EPS for the next quarter is expected at USD -0.37.
What is the analyst rating for Clene Inc.?
Based on the ratings of Clene Inc.'s stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.